{"disease":{"id":"cll-progression","name":"cll progression"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07342478","title":"ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":306,"lead_sponsor_name":"Newave Pharmaceutical Inc","has_results":false},{"nct_id":"NCT04149821","title":"Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}